Top Markets
#1 Islamic Coin Islamic Coin +151.51%
#2 Akedo Akedo +55.89%
#3 DOVU DOVU +48.37%
#4 Velvet Velvet +44.60%
#5 Black Phoenix Black Phoenix +34.05%
#6 Cross Cross +27.56%
#7 Cap Cap +19.95%
#8 DoubleZero DoubleZero +17.42%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.92%
#10 Pieverse Pieverse +9.84%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Classifica tra le azioni #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Prezzo delle azioni
$0.11725176
Ultima sincronizzazione: 2025-07-14
Capitalizzazione di mercato
$481.50K
Variazione (1 giorno)
-0.20%
Variazione (1 anno)
0.00%
Paese
FR
Scambia PHAXIAM Therapeutics S.A. (PHXM)

Categoria

Healthcare
Ricavi di PHAXIAM Therapeutics S.A. (PHXM)
Ricavi nel Jun 2024 TTM: $2.30M
Secondo gli ultimi rapporti finanziari di PHAXIAM Therapeutics S.A., i ricavi attuali dell'azienda (TTM) sono pari a $2.30M. Nel 2022, l'azienda ha registrato ricavi di $7.13M un aumento rispetto a i ricavi dell'anno 2021, che erano pari a $4.75M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per PHAXIAM Therapeutics S.A. da 2016 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $2.30M 56.82%
2023 $1.47M -79.44%
2022 $7.13M 50.00%
2021 $4.75M 4.97%
2020 $4.53M -23.61%
2019 $5.93M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 549,098.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 261,845.69%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 439,752.28%
BE